OWP Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
OWP Pharmaceuticals General Information
Description
Developer of food and drug administration (FDA) approved epilepsy medications intended to support patients and healthcare providers in neurology and psychiatry. The company specializes in developing and commercializing novel oral liquid formulations for epilepsy and associated psychiatric disorders, enabling clients to improve the lives of affected and under-resourced patients worldwide at an affordable cost.
Contact Information
Website
www.owppharma.comCorporate Office
- 701 Warrenville Road
- Suite 200
- Lisle, IL 60532
- United States
Corporate Office
- 701 Warrenville Road
- Suite 200
- Lisle, IL 60532
- United States
OWP Pharmaceuticals Timeline
OWP Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Mar-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 09-Sep-2025 | Completed | Generating Revenue | |||
| 3. Debt - General | 22-Jul-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 01-Aug-2016 | $950K | $1.85M | Completed | Generating Revenue | |
| 1. Seed Round | 01-Feb-2016 | $900K | $900K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
OWP Pharmaceuticals Patents
OWP Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | Active | 15-Apr-2025 | ||
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | Active | 15-Apr-2025 | ||
| US-20260315382-A1 | Atomoxetine hydrochloride oral suspension and use thereof | Pending | 15-Apr-2025 | ||
| US-20260315383-A1 | Atomoxetine hydrochloride oral suspension and use thereof | Pending | 15-Apr-2025 | ||
| US-20260315384-A1 | Atomoxetine hydrochloride oral suspension and use thereof | Pending | 15-Apr-2025 | A61K9/10 |
OWP Pharmaceuticals Signals
OWP Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Talanton | Impact Investing | Minority |
OWP Pharmaceuticals FAQs
-
When was OWP Pharmaceuticals founded?
OWP Pharmaceuticals was founded in 2014.
-
Where is OWP Pharmaceuticals headquartered?
OWP Pharmaceuticals is headquartered in Lisle, IL.
-
What is the size of OWP Pharmaceuticals?
OWP Pharmaceuticals has 21 total employees.
-
What industry is OWP Pharmaceuticals in?
OWP Pharmaceuticals’s primary industry is Drug Discovery.
-
Is OWP Pharmaceuticals a private or public company?
OWP Pharmaceuticals is a Private company.
-
What is OWP Pharmaceuticals’s current revenue?
The current revenue for OWP Pharmaceuticals is .
-
How much funding has OWP Pharmaceuticals raised over time?
OWP Pharmaceuticals has raised $10M.
-
Who are OWP Pharmaceuticals’s investors?
Talanton has invested in OWP Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process